Biotechnology

The five-year Biopharma SHAKTI initiative targets research, development, manufacturing scale-up, and private-sector co-investment across the biopharma value chain. Sustained public funding at this scale could de-risk early-stage biotech ventures and catalyse matching private capital. The programme directly addresses India's historical underinvestment in innovative biologics relative to its generics base.

Digitised submissions and expanded scientific capacity at CDSCO are expected to reduce approval timelines and improve regulatory predictability for biotech products. Faster, more transparent reviews lower the cost of capital for development-stage companies by compressing time-to-market uncertainty. This infrastructure upgrade also supports parallel approval pathways that could accelerate global commercialisation strategies.

India's push toward alignment with US FDA, EMA, and ICH standards could make Indian biotech assets more attractive to multinational partners and investors seeking globally licensable data packages. Harmonised clinical trial rules and parallel approval processes reduce duplicative development costs for companies targeting both domestic and export markets. Over time, this convergence strengthens India's credibility as a biotech innovation hub rather than solely a manufacturing base.

National alignment on analytical comparability, immunogenicity testing, and pharmacovigilance frameworks improves confidence in Indian biosimilars among domestic payers and international regulators. Stronger quality standards support broader adoption in regulated export markets such as the EU and US, where biosimilar penetration is accelerating. Indian biosimilar developers with robust quality systems stand to capture disproportionate share of a rapidly growing global biosimilar market.

Removing prior permission requirements for certain research activities, easing bioequivalence protocols, and enabling parallel regulatory submissions could materially shorten development timelines for Indian biotech companies. Reduced regulatory friction lowers the cost of conducting clinical trials domestically, making India a more competitive site for both local and multinational sponsors. These reforms compound the benefit of the digital regulatory platform by streamlining the full development-to-approval pathway.

Indian biotech start-ups face a structural financing shortfall for the multi-year, high-risk capital required to advance novel drug candidates through clinical development. Domestic institutional investors remain underexposed to early-stage biotech, and foreign venture capital has historically preferred more mature markets. Without dedicated long-duration funding vehicles, many promising programmes risk stalling between preclinical proof-of-concept and Phase II, limiting the pipeline of domestically originated biologics.

The benefits of digital regulatory platforms and expanded CDSCO scientific capacity depend on successful implementation, staff training, and sustained government prioritisation across political cycles. Delays or partial rollouts could leave approval timelines unchanged, eroding the competitive advantage India seeks to establish. Historical gaps between regulatory policy announcements and operational reality in India's drug-approval system represent a material execution risk.

As India moves up the biopharma value chain, it enters markets where Chinese CDMOs and biotech companies have already invested heavily in capacity, talent, and regulatory approvals. Chinese biosimilar manufacturers in particular have established cost and scale advantages in several therapeutic categories that Indian companies are now targeting. Competing on innovation rather than cost alone requires capabilities—clinical expertise, IP generation, global business development—that take years to build.

India's transition from generics to innovative biologics requires robust IP creation and protection, areas where the domestic ecosystem has historically been underdeveloped relative to the US, Europe, and China. Multinational companies may remain cautious about deep technology transfers or co-development partnerships without stronger IP enforcement track records. This limits access to cutting-edge platform technologies such as ADCs, mRNA, and cell and gene therapies that are driving the next wave of biotech value creation.

Scaling from generics manufacturing to biologics and advanced therapies requires specialised facilities, quality systems, and scientific talent that remain in short supply across India. The shift toward AI-driven drug discovery, advanced manufacturing, and resilient supply chains highlighted by industry leaders demands significant workforce upskilling and capital investment in new infrastructure. Bottlenecks in these areas could slow the pace at which Indian biotech companies can commercialise novel products even as the policy environment improves.